Methylation of BNIP3 and DAPK indicates lower response to chemotherapy and poor prognosis in gastric cancer

Oncology Reports

Volumn 25, Issue 2, 2011, Pages 513-518

  Sugita, Hirofumi ^a   Iida, Satoru ^a   Inokuchi, Mikito ^a   Kato, Keiji ^a   Ishiguro, Megumi ^a   Ishikawa, Toshiaki ^a   Takagi, Yoko ^a   Enjoji, Megumu ^a   Yamada, Hiroyuki ^a   Uetake, Hiroyuki ^a   Kojima, Kazuyuki ^a   Sugihara, Kenichi ^a  

^a Tokyo Medical and Dental University ^*  (Japan)

Author keywords

Bcl 2 adenovirus E1B 19 kDa interacting protein 3; Chemotherapy; Death associated protein kinase; Gastric cancer; Methylation

Indexed keywords

DEATH ASSOCIATED PROTEIN KINASE; FLUOROPYRIMIDINE; PROTEIN BCL 2; PROTEIN BNIP3;

ADULT; AGED; APOPTOSIS; ARTICLE; CANCER CHEMOTHERAPY; CANCER RECURRENCE; CLINICAL FEATURE; DISTANT METASTASIS; DNA METHYLATION; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; PROGNOSIS; PROGRESSION FREE SURVIVAL; STOMACH CANCER; TREATMENT RESPONSE;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; APOPTOSIS REGULATORY PROTEINS; BIOMARKERS, PHARMACOLOGICAL; CALCIUM-CALMODULIN-DEPENDENT PROTEIN KINASES; CARCINOMA; DNA METHYLATION; DRUG RESISTANCE, NEOPLASM; FEMALE; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; MALE; MEMBRANE PROTEINS; MIDDLE AGED; PROGNOSIS; PROTO-ONCOGENE PROTEINS; STOMACH NEOPLASMS; SURVIVAL ANALYSIS; TUMOR MARKERS, BIOLOGICAL; YOUNG ADULT;

EID: 78651350836     PISSN: 1021335X     EISSN: 17912431     Source Type: Journal    
DOI: 10.3892/or.2010.1085     Document Type: Article

References (39)

1. Hohenberger P and Gretschel S: Gastric cancer. Lancet 362: 305-315, 2003.
2. Dicken BJ, Bigam DL, Cass C, Mackey JR, Joy AA and Hamilton SM: Gastric adenocarcinoma-review and considerations for future directions. Ann Surg 241: 27-39, 2005. (Pubitemid 40044837)
3. Macdonald JS, Smalley SR, Benedetti J, et al: Chemoradiotherapy after surgery compared with surgery alone for adenocarcinoma of the stomach or gastroesophageal junction. N Eng J Med 345: 725-730, 2001.
4. Van Cutsem E, Moiseyenko VM, Tjulandin S, et al: Phase III study of docetaxel and cisplatin plus fluorouracil compared with cisplatin and fluorouracil as first-line therapy for advanced gastric cancer: a report of the V325 study group. J Clin Oncol 24: 4991-4997, 2006. (Pubitemid 46631401)
5. Koizumi W, Narahara H, Hara T, et al: S-1 plus cisplatin versus S-1 alone for first-line treatment of advanced gastric cancer (SPIRITS trial): a phase III trial. Lancet Oncol 9: 215-221, 2008.
6. Teodoridis JM, Strathdee G and Brown R: Epigenetic silencing mediated by CpG island methylation: potential as a therapeutic target and as a biomarker. Drug Resist Updat 7: 267-278, 2004. (Pubitemid 39469099)
7. Ishiguro M, Iida S, Uetake H, et al: Effect of combined therapy with low-dose 5-Aza-2′-deoxycytidine and irinotecan on colon cancer cell line HCT-15. Ann Surg Oncol 14: 1752-1762, 2007. (Pubitemid 46790993)
8. Satoh A, Toyota M, Itoh F, et al: DNA methylation and histone deacetylation associated with silencing DAP kinase gene expression in colorectal and gastric cancers. Br J Cancer 86: 1817-1823, 2002.
9. Satoh A, Toyota M, Itoh F, et al: Epigenetic inactivation of CHFR and sensitivity to microtubule inhibitors in gastric cancer. Cancer Res 63: 8606-8613, 2003. (Pubitemid 38064034)
10. Suzuki H, Itoh F, Toyota M, Kikuchi T, Kakiuchi H and Imai K: Inactivation of the 14-3-3 sigma gene is associated with 5′ CpG island hypermethylation in human cancers. Cancer Res 60: 4353-4357, 2000.
11. Yoshiura K, Kanai Y, Ochiai A, Shimoyama Y, Sugimura T and Hirohashi S: Silencing of the E-cadherin invasion-suppressor gene by CpG methylation in human carcinomas. Proc Natl Acad Sci USA 92: 7416-7419, 1995. (Pubitemid 27224296)
12. Iida S, Akiyama Y, Nakajima T, Ichikawa W, Nihei Z, Sugihara K and Yuasa Y: Alterations and hypermethylation of the p14(ARF) gene in gastric cancer. Int J Cancer 87: 654-658, 2000. (Pubitemid 30620407)
13. Belinsky SA, Palmisano WA, Gilliland FD, et al: Aberrant promoter methylation in bronchial epithelium and sputum from current and former smokers. Cancer Res 62: 2370-2377, 2002. (Pubitemid 34411720)
14. Ranzani GN, Luinetti O, Padovan LS, et al: p53 gene mutations and protein nuclear accumulation are early events in intestinal type gastric cancer but late events in diffuse type. Cancer Epidemiol Biomarkers Prev 4: 223-231, 1995.
15. Becker KF, Atkinson MJ, Reich U, Becker I, Nekarda H, Siewert JR and Höfler H: E-cadherin gene mutations provide clues to diffuse type gastric carcinomas. Cancer Res 54: 3845-3852, 1994.
16. Waki T, Tamura G, Tsuchiya T, Sato K, Nishizuka S and Motoyama T: Promoter methylation status of E-cadherin, hMLH1, and p16 genes in nonneoplastic gastric epithelia. Am J Pathol 161: 399-403, 2002.
17. Tamura G: Alterations of tumor suppressor and tumor-related genes in the development and progression of gastric cancer. World J Gastroenterol 12: 192-198, 2006.
18. Yu J, Tao Q, Cheng YY, et al: Promoter methylation of the Wnt/beta-catenin signaling antagonist Dkk-3 is associated with poor survival in gastric cancer. Cancer 115: 49-60, 2009.
19. Napieralski R, Ott K, Kremer M, et al: Methylation of tumor-related genes in neoadjuvant-treated gastric cancer: relation to therapy response and clinicopathologic and molecular features. Clin Cancer Res 13: 5095-5102, 2007. (Pubitemid 47502076)
20. Kato K, Iida S, Uetake H, et al: Methylated TMS1 and DAPK genes predict prognosis and response to chemotherapy in gastric cancer. Int J Cancer 122: 603-608, 2008. (Pubitemid 350308952)
21. Issa JP, Garcia-Manero G, Giles FJ, et al: Phase 1 study of low-dose prolonged exposure schedules of the hypomethylating agent 5-aza-2′- deoxycytidine in hematopoietic malignancies. Blood 103: 1635-1640, 2004. (Pubitemid 38268953)
22. Miyamoto K and Ushijima T: [DNA methylation and cancer-DNA methylation as a target of cancer chemotherapy]. Gan To Kagaku Ryoho 30: 2021-2029, 2003.
23. Morita S, Iida S, Kato K, Takagi Y, Uetake H and Sugihara K: The synergistic effect of 5-aza-2′-deoxycytidine and 5-fluorouracil on drug-resistant tumors. Oncology 71: 437-445, 2006.
24. Oizumi S, Isobe H, Ogura S, et al: Topoisomerase inhibitor-induced apoptosis accompanied by down-regulation of Bcl-2 in human lung cancer cells. Anticancer Res 22: 4029-4037, 2002. (Pubitemid 36134429)
25. Makin G and Dive C: Apoptosis and cancer chemotherapy. Trends Cell Biol 11: 22-26, 2001.
26. Fulda S and Debatin KM: Extrinsic versus intrinsic apoptosis pathways in anticancer chemotherapy. Oncogene 25: 4798-4811, 2006. (Pubitemid 44187627)
27. Reed JC: Bcl-2 family proteins. Oncogene 17: 3225-3236, 1998.
28. Labi V, Erlacher M, Kiessling S and Villunger A: BH3-only proteins in cell death initiation, malignant disease and anticancer therapy. Cell Death Differ 13: 1325-1338, 2006. (Pubitemid 44057468)
29. Strasser A: The role of BH3-only proteins in the immune system. Nat Rev Immunol 5: 189-200, 2005. (Pubitemid 40364821)
30. Willis SN and Adams JM: Life in the balance: how BH3-only proteins induce apoptosis. Curr Opin Cell Biol 17: 617-625, 2005.
31. Vande Velde C, Cizeau J, Dubik D, et al: BNIP3 and genetic control of necrosis-like cell death through the mitochondrial permeability transition pore. Mol Cell Biol 20: 5454-5468, 2000. (Pubitemid 30482883)
32. Mellor HR and Harris AL: The role of hypoxia-inducible BH3-only proteins BNIP3 and BNIP3L in cancer. Cancer Metastasis Rev 26: 553-566, 2007.
33. Murai M, Toyota M, Satoh A, et al: Aberrant DNA methylation associated with silencing BNIP3 gene expression in haematopoietic tumors. Br J Cancer 92: 1165-1172, 2005. (Pubitemid 40546685)
34. Akada M, Crnogorac-Jurcevic T, Lattimore S, et al: Intrinsic chemoresistance to gemcitabine is associated with decreased expression of BNIP3 in pancreatic cancer. Clin Cancer Res 11: 3094-3101, 2005. (Pubitemid 40525216)
35. Cohen O, Feinstein E and Kimchi A: DAP-kinase is a Ca2+/calmodulin- dependent, cytoskeletal-associated protein kinase, with cell death-inducing functions that depend on its catalytic activity. EMBO J 16: 998-1008, 1997. (Pubitemid 27113179)
36. Raveh T, Droguett G, Horwitz MS, DePinho RA and Kimchi A: DAP kinase activates a p19ARF/p53-mediated apoptotic checkpoint to suppress oncogenic transformation. Nat Cell Biol 3: 1-7, 2001. (Pubitemid 32114825)
37. Toyooka S, Toyooka KO, Miyajima K, et al: Epigenetic downregulation of death-associated protein kinase in lung cancers. Clin Cancer Res 9: 3034-3041, 2003. (Pubitemid 36993264)
38. Tang X, Khuri FR, Lee JJ, Kemp BL, Liu D, Hong WK and Mao L: Hypermethylation of the death-associated protein (DAP) kinase promoter and aggressiveness in stage I non-small-cell lung cancer. J Natl Cancer Inst 92: 1511-1516, 2000.
39. Fischer JR, Ohnmacht U, Rieger N, et al: Promoter methylation of RASSF1A, RARbeta and DAPK predict poor prognosis of patients with malignant mesothelioma. Lung Cancer 54: 109-116, 2006.